Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR ADC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04838548
What this trial is testing

Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Lepu Biopharma Co., Ltd. 87
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07589049
What this trial is testing

Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Sun Yat-sen University 42
Large-scale testing (Phase 3)Not Yet RecruitingNCT07680790
What this trial is testing

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 850
Testing effectiveness (Phase 2)Active Not RecruitingNCT05126719
What this trial is testing

Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Who this might be right for
Recurrent or Metastatic Nasopharyngeal Carcinoma
Lepu Biopharma Co., Ltd. 238
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07490119
What this trial is testing

Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer

Who this might be right for
RAS Wild Type mCRC
Fudan University 31
Early research (Phase 1)Looking for participantsNCT07054307
What this trial is testing

MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma

Who this might be right for
Penile Cancer
Jiyan Liu 10
Testing effectiveness (Phase 2)Looking for participantsNCT06827236
What this trial is testing

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Who this might be right for
Locally Advanced Breast CancerUnresectable Breast CarcinomaMetastatic Breast Cancer
BioNTech SE 380
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06475443
What this trial is testing

Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs

Who this might be right for
Metastatic Breast Cancer in the Brain
Henan Cancer Hospital 32
Large-scale testing (Phase 3)Active Not RecruitingNCT03529110
What this trial is testing

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Who this might be right for
Breast Cancer
Daiichi Sankyo 524
Early research (Phase 1)Looking for participantsNCT07612189
What this trial is testing

NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

Who this might be right for
Locally Advanced (Unresectable) or Metastatic Solid Tumors
NEOK Bio, Inc. 155
Early research (Phase 1)Ended earlyNCT03284723
What this trial is testing

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

Who this might be right for
Breast Neoplasms
Pfizer 95
Testing effectiveness (Phase 2)Looking for participantsNCT05688605
What this trial is testing

MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors
Lepu Biopharma Co., Ltd. 18
Testing effectiveness (Phase 2)Study completedNCT04205630
What this trial is testing

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Who this might be right for
Endometrial Cancer
Byondis B.V. 64
Testing effectiveness (Phase 2)Looking for participantsNCT07070232
What this trial is testing

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Who this might be right for
Advanced Solid Tumor
BioNTech SE 1,438
Large-scale testing (Phase 3)Looking for participantsNCT06989112
What this trial is testing

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Who this might be right for
Endometrial Cancer
AstraZeneca 600
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07757230
What this trial is testing

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 87
Testing effectiveness (Phase 2)Looking for participantsNCT07712029
What this trial is testing

Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive

Who this might be right for
Advanced Refractory Solid TumorsEGFR Gene Overexpression
Tianjin Medical University Second Hospital 32
Testing effectiveness (Phase 2)Looking for participantsNCT07381075
What this trial is testing

A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
West China Hospital 90
Testing effectiveness (Phase 2)Looking for participantsNCT07111520
What this trial is testing

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
BioNTech SE 880
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07394244
What this trial is testing

Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma

Who this might be right for
Cutaneous Squamous Cell Carcinoma (CSCC)
Fudan University 38
Next Page